[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2484068B1 - A pharmaceutical composition containing ketamine and amitriptyline - Google Patents

A pharmaceutical composition containing ketamine and amitriptyline Download PDF

Info

Publication number
ES2484068B1
ES2484068B1 ES201330152A ES201330152A ES2484068B1 ES 2484068 B1 ES2484068 B1 ES 2484068B1 ES 201330152 A ES201330152 A ES 201330152A ES 201330152 A ES201330152 A ES 201330152A ES 2484068 B1 ES2484068 B1 ES 2484068B1
Authority
ES
Spain
Prior art keywords
amitriptyline
pharmaceutical composition
composition containing
ketamine
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201330152A
Other languages
Spanish (es)
Other versions
ES2484068A1 (en
Inventor
Ana MÍNGUEZ MARTÍ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES201330152A priority Critical patent/ES2484068B1/en
Publication of ES2484068A1 publication Critical patent/ES2484068A1/en
Application granted granted Critical
Publication of ES2484068B1 publication Critical patent/ES2484068B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)

Abstract

Consiste en una composición farmacéutica que contiene amitriptilina y ketamina, formada por:#- Amitriptilina, 2%-4% en peso#- Ketamina, 2%-3% en peso#- Propilenglicol, 5%-7% en peso#- Una emulsión no iónica del tipo o/w (de aceite en agua), 86%-90% en peso.It consists of a pharmaceutical composition containing amitriptyline and ketamine, consisting of: # - Amitriptyline, 2% -4% by weight # - Ketamine, 2% -3% by weight # - Propylene glycol, 5% -7% by weight # - A non-ionic emulsion of the type o / w (oil in water), 86% -90% by weight.

Description



imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

Claims (1)



 imagen1image 1
ES201330152A 2013-02-08 2013-02-08 A pharmaceutical composition containing ketamine and amitriptyline Expired - Fee Related ES2484068B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201330152A ES2484068B1 (en) 2013-02-08 2013-02-08 A pharmaceutical composition containing ketamine and amitriptyline

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330152A ES2484068B1 (en) 2013-02-08 2013-02-08 A pharmaceutical composition containing ketamine and amitriptyline

Publications (2)

Publication Number Publication Date
ES2484068A1 ES2484068A1 (en) 2014-08-08
ES2484068B1 true ES2484068B1 (en) 2015-04-16

Family

ID=51264531

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330152A Expired - Fee Related ES2484068B1 (en) 2013-02-08 2013-02-08 A pharmaceutical composition containing ketamine and amitriptyline

Country Status (1)

Country Link
ES (1) ES2484068B1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
JOP20200156A1 (en) 2017-12-22 2022-10-30 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
US20230117657A1 (en) 2019-03-05 2023-04-20 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2315815A1 (en) * 2000-07-19 2002-01-19 Peter R. Ford Topical pain relief composition and carrier
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
WO2006022611A2 (en) * 2004-06-26 2006-03-02 Binnur Ozturk Neuropathy cream
US20080095831A1 (en) * 2006-08-10 2008-04-24 Mc Graw Thomas L Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent

Also Published As

Publication number Publication date
ES2484068A1 (en) 2014-08-08

Similar Documents

Publication Publication Date Title
ES2484068B1 (en) A pharmaceutical composition containing ketamine and amitriptyline
CL2014001930A1 (en) Pharmaceutical formulation comprising an angiopoietin 2 (anti-ang2) antibody.
ES2620754T3 (en) Use of 5-androstane (alkyl) -3,5,6-triol in the preparation of neuroprotective drugs
BR112016000489A2 (en) compound, pharmaceutical composition comprising it, use of the composition and methods for making compounds
ES2637421T3 (en) Topical compositions comprising fold-OB variants
ES2643814T3 (en) Forklift equipped with stabilization means
CO2017006898A2 (en) Insulin glargine / lixisenatide fixed ratio formulation
CL2014003148A1 (en) Aqueous pharmaceutical composition containing a biological therapeutic agent and guanidine or a guanidine derivative and an injection that includes the composition.
BR112015030268A2 (en) pharmaceutical composition, container, kit, and method for preparing a composition
UA115373C2 (en) AMG 416 (VELCALSETID) STABLE LIQUID COMPOSITION
MA49116A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN
CL2014003237A1 (en) Stable pharmaceutical formulation comprising an anti-dll4 antibody (human delta 4 ligand); and kit comprising the composition in a package and instructions.
ES2543850A2 (en) Use of sod metal mimetic complexes as food agents and as cosmetics (Machine-translation by Google Translate, not legally binding)
PA8747601A1 (en) MARKING WITH RADIOACTIVE FLUOR
CL2015002389A1 (en) Herbicidal compositions containing isoxabena and flufenaceto.
FR3013964B1 (en) COMPOSITION COMPRISING AQUEOUS MEDIUM
ES2510403T3 (en) Antioxidant, synergistic composition
MX369778B (en) Glycogen-based water solubility enhancers.
ES2487219T3 (en) Use of an N-vinillactam / vinylimidazole copolymer as dispersing agent
ES2441468B1 (en) SOLID PHARMACEUTICAL COMPOSITION OF CATIÓNIC EXCHANGE RESIN.
CL2015003736A1 (en) Nalmefene salts as medicines to reduce alcohol consumption or to prevent excessive alcohol consumption
ES2585558T3 (en) Use of 3-carboxy-N-ethyl-N, N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
ES2642624T3 (en) Modified Canine Leptin Polypeptides
ES2616686T3 (en) Liquid vitamin E concentrated compositions
ES2526935B2 (en) Compounds for the treatment of Leishmania infections

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2484068

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150416

FD2A Announcement of lapse in spain

Effective date: 20220624